Beijing Tiantan Biological Products Co., Ltd.

SHSE:600161 Stock Report

Market Cap: CN¥43.2b

Beijing Tiantan Biological Products Valuation

Is 600161 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600161 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600161 (CN¥22.1) is trading below our estimate of fair value (CN¥25.18)

Significantly Below Fair Value: 600161 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600161?

Key metric: As 600161 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600161. This is calculated by dividing 600161's market cap by their current earnings.
What is 600161's PE Ratio?
PE Ratio34.3x
EarningsCN¥1.27b
Market CapCN¥43.23b

Price to Earnings Ratio vs Peers

How does 600161's PE Ratio compare to its peers?

The above table shows the PE ratio for 600161 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.8x
002252 Shanghai RAAS Blood Products
27.6x17.0%CN¥50.0b
688363 Bloomage BioTechnology
66.1x34.7%CN¥29.0b
301301 Yili Chuanning BiotechnologyLtd
22.1x14.9%CN¥30.2b
300122 Chongqing Zhifei Biological Products
19.6x45.1%CN¥71.7b
600161 Beijing Tiantan Biological Products
34.3x19.7%CN¥43.2b

Price-To-Earnings vs Peers: 600161 is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the peer average (33.8x).

Price to Earnings Ratio vs Industry

How does 600161's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600161 34.3xIndustry Avg. 36.6xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600161 is good value based on its Price-To-Earnings Ratio (34.3x) compared to the CN Biotechs industry average (36.6x).

Price to Earnings Ratio vs Fair Ratio

What is 600161's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600161 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34.3x
Fair PE Ratio30.6x

Price-To-Earnings vs Fair Ratio: 600161 is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the estimated Fair Price-To-Earnings Ratio (30.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600161 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥22.10
CN¥29.51
+33.5%
6.4%CN¥31.60CN¥26.43n/a4
Nov ’25CN¥21.51
CN¥29.51
+37.2%
6.4%CN¥31.60CN¥26.43n/a4
Oct ’25CN¥25.14
CN¥29.92
+19.0%
7.1%CN¥31.67CN¥26.43n/a4
Sep ’25CN¥23.77
CN¥29.09
+22.4%
8.8%CN¥31.67CN¥26.43n/a4
Aug ’25CN¥24.25
CN¥28.25
+16.5%
8.6%CN¥31.67CN¥26.43n/a3
Jul ’25CN¥24.94
CN¥28.25
+13.3%
8.6%CN¥31.67CN¥26.43n/a3
Jun ’25CN¥23.62
CN¥28.25
+19.6%
8.6%CN¥31.67CN¥26.43n/a3
May ’25CN¥23.98
CN¥26.55
+10.7%
0.5%CN¥26.67CN¥26.43n/a2
Apr ’25CN¥22.33
CN¥26.23
+17.4%
8.0%CN¥28.33CN¥24.13n/a2
Mar ’25CN¥23.28
CN¥26.23
+12.7%
8.0%CN¥28.33CN¥24.13n/a2
Feb ’25CN¥21.80
CN¥26.06
+19.6%
6.7%CN¥28.33CN¥24.13n/a3
Jan ’25CN¥25.78
CN¥26.06
+1.1%
6.7%CN¥28.33CN¥24.13n/a3
Dec ’24CN¥26.38
CN¥26.06
-1.2%
6.7%CN¥28.33CN¥24.13n/a3
Nov ’24CN¥23.95
CN¥24.95
+4.2%
2.6%CN¥25.73CN¥24.13CN¥21.513
Oct ’24CN¥21.36
CN¥24.95
+16.8%
2.6%CN¥25.73CN¥24.13CN¥25.143
Sep ’24CN¥20.90
CN¥25.36
+21.4%
1.4%CN¥25.73CN¥25.00CN¥23.772
Aug ’24CN¥20.93
CN¥25.36
+21.2%
1.4%CN¥25.73CN¥25.00CN¥24.252
Jul ’24CN¥22.62
CN¥25.36
+12.1%
1.4%CN¥25.73CN¥25.00CN¥24.942
Jun ’24CN¥22.07
CN¥25.36
+14.9%
1.4%CN¥25.73CN¥25.00CN¥23.622
Dec ’23CN¥18.57
CN¥18.39
-1.0%
21.3%CN¥22.31CN¥14.47CN¥26.382
Nov ’23CN¥16.92
CN¥18.39
+8.7%
21.3%CN¥22.31CN¥14.47CN¥23.952

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

7D

-3.9%

1Y

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

7D

-2.0%

1Y

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

7D

-1.2%

1Y

18.8%